Tradename:

Lamifen

Composition:

Each tablet contains:

Terbinafine 250 mg

Auxiliary components: hydroxypropyl cellulose, hypromellose, microcrystalline cellulose, silicon dioxide, calcium stearate.

Properties:

Antifungal agent, belongs to the group of aplylamines, has a wide spectrum of antifungal action. In low concentrations, it has a fungicidal effect on dermatophytes Trichophyton spp. (Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans, Trichophyton verrucosum, Trichophyton violaceum), Microsporum canis,

Epidermophyton floccosum, molds (eg, Scopulariopsis brevicaulis), yeast albicans, mainly albicans. For Candida spp. and their mycelial forms, depending on the type of fungus, have a fungicidal or fungistatic effe Terbinafine disrupts the early stage of biosynthesis of the main component of the cell membrane of the fungus ergosterol by inhibiting the enzyme squalene epoxidase.

When administered orally, it is not effective in the treatment of varicoloured lichen caused by Pityrosporum ovale, Pityrosporum orbiculare, Malassezia furfur.

Indications:

Mycoses of the scalp (trichophytosis, microsporia); fungal diseases of the skin and nails (onychomycosis) caused by Trichophyton spp. (T. rubrum, T. mentagrophytes, T.

verrucosum, T. violaceum), Microsporum spp. (M. canis, M. gypseum) and Epidermophyton floccosum; severe, widespread dermatomycosis of the smooth skin of the trunk and extremities, requiring systemic treatment; candidiasis of the skin and mucous membranes.

Method of administration and dosage:

Is taken internally. The duration of the course of treatment and the dosage regimen are set individually and depend on the localization the process and the severity of the disease.

adults – at a dose of 250 mg 1 time / day. The

2-6 weeks.

Contraindications:

Acute or chronic liver disease; children under 2 years old; lactation period; hypersensitivity to terbinafine.

Carefully.

Pregnancy; renal failure; alcoholism; oppression of bone marrow hematopoiesis; tumors; metabolic diseases; occlusive vascular disease of the extremities.

Precautions:

Irregular use of terbinafine or premature discontinuation of treatment can lead to a relapse of the disease. The duration of therapy can also be influenced by such factors as the presence of concomitant diseases, the condition of the nails with onychomycosis at the beginning of the course of treatment. If after 2 weeks of treatment of the skin infection there is no improvement in the condition, it is necessary to re-determine the causative agent of the disease and its sensitivity to the drug. Systemic use in onychomycosis is justified in the case of total damage to most nails, th presence of pronounced subungual hyperkeratosis, and the ineffectiveness of previous local therapy. In the treatment of onychomycosis, a laboratory-confirmed clinical response is usually observed several months after mycological cure and discontinuation of the course of treatment, which is due to the rate of regrowth of a healthy nail. Removal of nail plates in the treatment of onychomycosis of the hands within 3 weeks and onychomycosis of the feet within 6 weeks is not required. In the presence of liver disease, terbinafine clearance may be reduced.

Side effects:

From the side of the central nervous system: often – headache, dizziness.

From the hematopoietic system: very rarely (<0.01%) – neutropenia, agranulocytosis, thrombocytopenia.

From the immune system: rarely anaphylactoid reactions, including angioedema, exacerbation of systemic lupus erythematosus.

Skin and subcutaneous tissue disorders: oft – rash, urticaria; very rarely – psoriasis-like skin rashes, exacerbation of psoriasis, Stevens-

Johnson syndrome, toxic epidermal necrolysis, hair loss, acute generalized exanthematous pustulosis.

From the musculoskeletal system: often arthralgia, myalgia.

General reactions: very rarely – fatigue.

Storage method:

At a temperature not higher than 30 degrees.

Packaging:

The cardboard box contains 2 blisters of 7 tablets.